Get the Stockscreener App
2.89
0.52%
0.00
Entera Bio Ltd stock is traded at $2.89, with a volume of 263.98K.
It is up +0.52% in the last 24 hours and up +46.72% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
See More
Previous Close:
$2.89
Open:
$2.83
24h Volume:
263.98K
Relative Volume:
0.11
Market Cap:
$502.98M
Revenue:
$42,000
Net Income/Loss:
$-12.38M
P/E Ratio:
-10.97
EPS:
-0.2634
Net Cash Flow:
$-9.61M
1W Performance:
-4.44%
1M Performance:
+46.72%
6M Performance:
+104.58%
1Y Performance:
+45.25%
1-Day Range:
$2.82
$2.97
1-Week Range:
$2.75
$3.0592
52-Week Range:
$0.91
$4.20
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
2.905 | 500.38M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
515.76 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.65 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.87 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.83 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement - MarketBeat
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7% - MarketBeat
Entera Bio at Canaccord Genuity: oral osteoporosis push advances By Investing.com - Investing.com Canada
Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants - Stock Titan
Entera Bio shares slip as Q2 loss comes in wider than expected - Yahoo Finance
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com Nigeria
Entera Bio misses Q2 estimates, reports wider loss - Investing.com
Entera Bio Ltd. (ENTX) stock price, news, quote and history - au.finance.yahoo.com
Entera Bio (NASDAQ:ENTX) Upgraded to Sell at Wall Street Zen - MarketBeat
Entera Bio (NASDAQ:ENTX) Announces Earnings Results - MarketBeat
Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million - scanx.trade
Entera Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Entera Bio Reports Q2 2026 Loss and $275 Million Private Placement - Moomoo
Entera Bio Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Entera Bio (ENTX) awards 180,000 options to Chief of R&D - Stock Titan
Entera Q2 2026 earnings: Phase 3 preparation widened the loss - TradingKey
ENTX: FDA-aligned Phase 3 for EB613 and $275M financing secure pipeline progress and cash runway - TradingView
Entera Bio Ltd. Q2 2026: Revenue $0M, Net loss $7.31M, EPS ($0.14) — 10-Q Summary - TradingView
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entera Bio Sees Funding Sufficient Into 2030 >ENTX - Moomoo
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ENTX|Entera Bio Ltd|Price:2.890|Chg%:+0.020 - TradingKey
Entera Bio data selected for ASBMR plenary session - PharmaTimes
ENTX Q2'26 Earnings: EPS estimate is (0.08) USD - TradingView
Entera Bio (ENTX): Longitude entities report 4.6% ownership, Seven Fleet 4.1% - Stock Titan
Entera Bio (NASDAQ:ENTX) Trading Down 2.1%Here's What Happened - MarketBeat
BVF Partners Wins Board Designation Rights at Entera Bio with 9.99% Stake - TradingView
Seven Fleet funds disclose 4.1% Entera Bio (ENTX) stake and shared voting power - stocktitan.net
Entera Bio (ENTX) sees BVF build 9.99% stake after $275M financing - Stock Titan
Entera Bio (ENTX) stake of 12.25M shares reported by TCG Crossover - stocktitan.net
Vivo Opportunity group (NASDAQ: ENTX) discloses 12.3M-share holding in Entera Bio - Stock Titan
Entera Bio’s EB613 data selected for plenary poster at ASBMR - Investing.com
Entera Bio Ltd. (IL0011429839.SG) Stock Forum & Discussion - Yahoo! Finance Canada
Entera Bio’s EB613 data selected for plenary poster at ASBMR By Investing.com - Investing.com Australia
Entera Bio’s oral bone-building candidate selected for ASBMR plenary - Stock Titan
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Weekly Recap: Entera Bio $275M placement and director resignations - TradingView
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Entera Bio CEO Miranda Toledano to speak at Canaccord Genuity conference - scanx.trade
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE - marketscreener.com
Why the World's Leading Healthcare Funds All Wanted a Piece of Entera Bio (NASDAQ: ENTX) - TradingView
Entera Bio raises $275M in oversubscribed placement, shares rebound on funding news - scanx.trade
Entera Bio Raises $275 Million in Market-Priced Private Placement Led by BVF - TradingView
ENTX|Entera Bio Ltd|Price:3.930|Chg%:+1.880 - TradingKey
Entera Bio Ltd. announced that it expects to receive $274.999977 million in funding from a group of investors - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Entera Bio Shares Climb on $275M Private Placement - Moomoo
Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entera Bio stock surges on $275M private placement By Investing.com - Investing.com Nigeria
Entera Bio raises $275m for Phase III osteoporosis drug trialGlobes - Globes - Israel Business News
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entera Bio Ltd Stock (ENTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Mar 05 '26 |
Buy |
1.23 |
10,000 |
12,300 |
188,098 |
| Rubin Steven D | Director |
Feb 12 '26 |
Buy |
1.49 |
5,000 |
7,450 |
15,000 |
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
2.24%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):